MALVERN, Pa. — September 2, 2025 — Leads & Copy — Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York, September 8-10, 2025, and a panel at Biotech on Tap 2025 in Munich, Germany, September 24-26, 2025.
Dr. Musunuri looks forward to meeting with key investors and broadening Ocugen’s reach into the European investment community.
Ocugen’s executive team will also conduct one-on-one meetings to showcase the company’s business and clinical development strategy.
Dr. Musunuri’s sessions include:
- H.C. Wainwright 27th Annual Global Investment Conference: September 8, 2025, 5 p.m. ET, Lotte New York Palace Hotel, NYC.
- Biotech on Tap: September 25, 2025, 3:30 p.m. CET, EY Auditorium, Munich, Germany.
A live video webcast of the fireside chat will be available on the Ocugen investor site, with a replay archived for 90 days.
Ocugen, Inc. is focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address unmet medical needs for inherited retinal diseases and other blindness diseases.
Tiffany Hamilton, AVP, Head of Communications, Tiffany.Hamilton@ocugen.com
Source: Ocugen, Inc.
